JP2016536368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536368A5 JP2016536368A5 JP2016552435A JP2016552435A JP2016536368A5 JP 2016536368 A5 JP2016536368 A5 JP 2016536368A5 JP 2016552435 A JP2016552435 A JP 2016552435A JP 2016552435 A JP2016552435 A JP 2016552435A JP 2016536368 A5 JP2016536368 A5 JP 2016536368A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- composition
- deficiency
- hemophilia
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361898884P | 2013-11-01 | 2013-11-01 | |
| US61/898,884 | 2013-11-01 | ||
| US201361918341P | 2013-12-19 | 2013-12-19 | |
| US61/918,341 | 2013-12-19 | ||
| PCT/US2014/063676 WO2015066606A2 (en) | 2013-11-01 | 2014-11-03 | Compositions and methods for increasing the half-life of factor xa |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016536368A JP2016536368A (ja) | 2016-11-24 |
| JP2016536368A5 true JP2016536368A5 (enExample) | 2017-12-14 |
| JP6629744B2 JP6629744B2 (ja) | 2020-01-15 |
Family
ID=53005403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552435A Expired - Fee Related JP6629744B2 (ja) | 2013-11-01 | 2014-11-03 | 第Ｘａ因子の半減期を延ばす組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160235824A1 (enExample) |
| EP (1) | EP3063170A4 (enExample) |
| JP (1) | JP6629744B2 (enExample) |
| CA (1) | CA2928762A1 (enExample) |
| WO (1) | WO2015066606A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2761730T3 (es) | 2013-01-31 | 2020-05-20 | Pfizer | Composiciones y procedimientos para contrarrestar la inhibición del factor Xa |
| EP3049434A1 (en) | 2013-09-24 | 2016-08-03 | Pfizer Inc. | Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262047B1 (en) | 1996-10-11 | 2001-07-17 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
| US6369080B2 (en) | 1996-10-11 | 2002-04-09 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
| WO1998046628A1 (en) | 1997-04-14 | 1998-10-22 | Cor Therapeutics, Inc. | SELECTIVE FACTOR Xa INHIBITORS |
| GB9908838D0 (en) * | 1998-09-11 | 1999-06-16 | Univ London | Fibroblast inhibitor |
| US6905683B2 (en) * | 2000-05-03 | 2005-06-14 | Novo Nordisk Healthcare A/G | Human coagulation factor VII variants |
| MX2008006313A (es) * | 2005-11-15 | 2008-11-06 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| EP1867660A1 (en) * | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| EP2915564B1 (en) * | 2007-09-28 | 2020-11-04 | Portola Pharmaceuticals, Inc. | Antidotes for factor XA inhibitors and methods of using the same |
| US20100297257A1 (en) * | 2007-11-09 | 2010-11-25 | National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) | Anticoagulant antagonist and hemophillia procoagulant |
| MX2011004907A (es) * | 2008-11-14 | 2011-07-29 | Portola Pharm Inc | Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre. |
| ES2605801T3 (es) * | 2009-07-15 | 2017-03-16 | Portola Pharmaceuticals, Inc. | Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia |
| GB2485590A (en) * | 2010-11-22 | 2012-05-23 | Univ Ruprecht Karis Heidelberg | Method for detecting at least one direct factor Xa inhibitors |
| US20160015793A1 (en) * | 2012-02-16 | 2016-01-21 | Portola Pharmacueticals, Inc. | Modulation of factor xa inhibitor mediated blood loss by partial and transient administration of antidote |
| FR3000895B1 (fr) * | 2013-01-11 | 2017-02-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa | Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques |
| ES2761730T3 (es) * | 2013-01-31 | 2020-05-20 | Pfizer | Composiciones y procedimientos para contrarrestar la inhibición del factor Xa |
-
2014
- 2014-11-03 EP EP14857821.4A patent/EP3063170A4/en not_active Withdrawn
- 2014-11-03 WO PCT/US2014/063676 patent/WO2015066606A2/en not_active Ceased
- 2014-11-03 US US15/031,077 patent/US20160235824A1/en not_active Abandoned
- 2014-11-03 JP JP2016552435A patent/JP6629744B2/ja not_active Expired - Fee Related
- 2014-11-03 CA CA2928762A patent/CA2928762A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Naudin et al. | Factor XII contact activation | |
| Draxler et al. | Plasmin: a modulator of immune function | |
| Key et al. | Coagulation factor concentrates: past, present, and future | |
| Collen | The plasminogen (fibrinolytic) system | |
| Okamoto et al. | Thrombomodulin: a bifunctional modulator of inflammation and coagulation in sepsis | |
| Yaron et al. | Fibrinolytic serine proteases, therapeutic serpins and inflammation: fire dancers and firestorms | |
| Pryzdial et al. | Blood coagulation dissected | |
| Hedner et al. | First 20 years with recombinant FVIIa (NovoSeven) | |
| Rengasamy et al. | Bioactive peptides and proteins as alternative antiplatelet drugs | |
| Pathak et al. | Cell receptor and cofactor interactions of the contact activation system and factor XI | |
| Afosah et al. | Factor IX (a) inhibitors: an updated patent review (2003-present) | |
| Chun et al. | Case 1—2005: Cardiac surgery in congenital afibrinogenemia with thrombo-occlusive disease | |
| Ali et al. | The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease | |
| JP2016536368A5 (enExample) | ||
| Zhong et al. | Coagulation factor XI vaccination: an alternative strategy to prevent thrombosis | |
| Mackman et al. | Platelet polyphosphate: an endogenous activator of coagulation factor XII | |
| Subramaniam et al. | Post-transcriptional, post-translational and pharmacological regulation of tissue factor pathway inhibitor | |
| Seligsohn et al. | Inherited deficiencies of coagulation factors II, V, VII, XI and XIII and the combined deficiencies of Factors V and VIII and of the Vitamin K dependent factors | |
| US20250099540A1 (en) | Methods and pharmaceutical composition for treating thrombotic disorders | |
| US20160235824A1 (en) | Compositions and Methods for Increasing the Half-Life of Factor XA | |
| Pilli | Understanding the clotting cascade, regulators, and clinical modulators of coagulation | |
| Nellenbach et al. | Peptide mimetic drugs for modulating thrombosis and hemostasis | |
| Levi | The Coagulation System in Sepsis | |
| ES2532978T3 (es) | Especialidades farmacéuticas para el tratamiento de trastornos de coagulación de la sangre que contienen concentrado de factor XIa sin trombina | |
| Vande Vusse et al. | Prohemostatic therapy: the rise and fall of aprotinin |